ID: ALA460807

Max Phase: Preclinical

Molecular Formula: C11H21F3O4S

Molecular Weight: 306.35

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCCCCCCCS(=O)(=O)CC(O)(O)C(F)(F)F

Standard InChI:  InChI=1S/C11H21F3O4S/c1-2-3-4-5-6-7-8-19(17,18)9-10(15,16)11(12,13)14/h15-16H,2-9H2,1H3

Standard InChI Key:  OLWUZZLDMIIGAL-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 306.35

Molecular Weight (Monoisotopic): 306.1113

AlogP: 2.00

#Rotatable Bonds: 9

Polar Surface Area: 74.60

Molecular Species: NEUTRAL

HBA: 4

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 4

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 7.64

CX Basic pKa:

CX LogP: 2.24

CX LogD: 2.04

Aromatic Rings: 0

Heavy Atoms: 19

QED Weighted: 0.50

Np Likeness Score: -0.31

References

1. Harada T, Nakagawa Y, Wadkins RM, Potter PM, Wheelock CE..  (2009)  Comparison of benzil and trifluoromethyl ketone (TFK)-mediated carboxylesterase inhibition using classical and 3D-quantitative structure-activity relationship analysis.,  17  (1): [PMID:19062296] [10.1016/j.bmc.2008.11.008]

2. Wheelock CE, Severson TF, Hammock BD..  (2001)  Synthesis of new carboxylesterase inhibitors and evaluation of potency and water solubility.,  14  (12): [PMID:11743738] [10.1021/tx015508+]

3. Mouchlis VD, Morisseau C, Hammock BD, Li S, McCammon JA, Dennis EA..  (2016)  Computer-aided drug design guided by hydrogen/deuterium exchange mass spectrometry: A powerful combination for the development of potent and selective inhibitors of Group VIA calcium-independent phospholipase A₂.,  24  (20): [PMID:27320659] [10.1016/j.bmc.2016.05.009]

Source

Source(1):

• Scientific Literature